These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 28223446)

  • 21. Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis.
    Marengo A; Rosso C; Bugianesi E
    Annu Rev Med; 2016; 67():103-17. PubMed ID: 26473416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological management of nonalcoholic fatty liver disease.
    Barb D; Portillo-Sanchez P; Cusi K
    Metabolism; 2016 Aug; 65(8):1183-95. PubMed ID: 27301803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of nonalcoholic fatty liver disease in the Middle East.
    Sanai FM; Abaalkhail F; Hasan F; Farooqi MH; Nahdi NA; Younossi ZM
    World J Gastroenterol; 2020 Jul; 26(25):3528-3541. PubMed ID: 32742124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonalcoholic fatty liver disease: Evolving paradigms.
    Lonardo A; Nascimbeni F; Maurantonio M; Marrazzo A; Rinaldi L; Adinolfi LE
    World J Gastroenterol; 2017 Sep; 23(36):6571-6592. PubMed ID: 29085206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Approach to patients with liver diseases].
    Brůha R
    Vnitr Lek; 2015 Nov; 61 Suppl 4():4s6-12. PubMed ID: 26667615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes.
    Doycheva I; Patel N; Peterson M; Loomba R
    J Diabetes Complications; 2013; 27(3):293-300. PubMed ID: 23312215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonalcoholic steatohepatitis.
    Brunt EM
    Semin Liver Dis; 2004 Feb; 24(1):3-20. PubMed ID: 15085483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonalcoholic fatty liver disease: a systematic review.
    Rinella ME
    JAMA; 2015 Jun; 313(22):2263-73. PubMed ID: 26057287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes.
    Kuchay MS; Choudhary NS; Mishra SK; Misra A
    Diabetes Metab Syndr; 2020; 14(6):2233-2239. PubMed ID: 33336648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission.
    Wild SH; Walker JJ; Morling JR; McAllister DA; Colhoun HM; Farran B; McGurnaghan S; McCrimmon R; Read SH; Sattar N; Byrne CD;
    Diabetes Care; 2018 Feb; 41(2):341-347. PubMed ID: 29167212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CROATIAN GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE.
    Virović Jukić L; Grgurević I; Mikolašević I; Filipec Kanižaj T; Milić S; Mrzljak A; Premužić M; Hrstić I; Knežević-Štromar I; Ljubičić N; Ostojić R; Stojsavljević Shapeski S; Amerl-Šakić V; Marković NB; Rađa M; Soldo D; Sobočan N; Lalovac M; Puljiz Ž; Podrug K; Ladić D
    Acta Clin Croat; 2021 Dec; 60(Suppl 2):36-52. PubMed ID: 35528151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are statins 'IDEAL' for non-alcoholic fatty liver disease?
    Athyros VG; Katsiki N; Karagiannis A; Mikhailidis DP
    Curr Med Res Opin; 2014 Feb; 30(2):229-31. PubMed ID: 24127654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Liver disorders in diabetic patients].
    Brůha R; Dvořák K; Petrtýl J
    Vnitr Lek; 2013 Jul; 59(7):546-50. PubMed ID: 23909257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver.
    Godinez-Leiva E; Bril F
    Curr Hypertens Rev; 2021; 17(2):94-111. PubMed ID: 33302841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers.
    Basu R; Noureddin M; Clark JM
    Mayo Clin Proc; 2022 Sep; 97(9):1700-1716. PubMed ID: 36058582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Watanabe S; Hashimoto E; Ikejima K; Uto H; Ono M; Sumida Y; Seike M; Takei Y; Takehara T; Tokushige K; Nakajima A; Yoneda M; Saibara T; Shiota G; Sakaida I; Nakamuta M; Mizuta T; Tsubouchi H; Sugano K; Shimosegawa T; ;
    J Gastroenterol; 2015 Apr; 50(4):364-77. PubMed ID: 25708290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus.
    Ferguson D; Finck BN
    Nat Rev Endocrinol; 2021 Aug; 17(8):484-495. PubMed ID: 34131333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD).
    Lomonaco R; Chen J; Cusi K
    Ther Adv Endocrinol Metab; 2011 Oct; 2(5):211-25. PubMed ID: 23148186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prevalence and harm of nonalcoholic fatty liver disease].
    Shao YL; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):10-13. PubMed ID: 30685917
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.